Business
Sona Provides Update on First-In-Human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first...
About this update from Sona Nanotech, Inc.
[{"type":"text","content":"Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients have now been completed and treatment on the second cohort of patients has been approved with Sona's Chief Medical Officer arriving in Santiago this past weekend to oversee further treatments.","length":738,"tagName":"p"},{"type":"text","content":"Sona CMO, Dr. Carman Giacomantonio, commented, "We are very pleased with the progress of our Early Feasibility Study, which has provided rich learnings in the real-world application our THT therapy in humans. It has been a pleasure to work with the clinicians and research team at Bradford Hill. We have treated a variety of melanoma tumor types in our first cohort and have encountered no significant adverse health events in patients. As we proceed with the second cohort of patients, we have reason for optimism based on early clinical responses and tumor biopsy results for patients treated so far. We look forward to completing the targeted number of patients by the end of September and then running the more extensive scientific analysis to fully assess immune engagement in treated tumors following THT."","length":822,"tagName":"p"},{"type":"text","content":"David Regan, Sona's CEO, commented, "We are encouraged by the progress of our first-in-human clinical study and pleased to be progressing toward having validating clinical data that will further complement our existing preclinical data. We also excitedly anticipate additional scientific insights into our novel technology from studies planned for submission to leading scientific journals in the fall that, combined with our clinical study, will provide for a more comprehensive data package. Furthermore, with our previously announced ethics approval secured for a larger clinical trial in Canada, we are currently working to incorporate the significant learnings to date from our Early ...